Cancer Diagnostics by Analyzing Urea Cycle Enzymes

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

An innovative method to diagnose and potentially treat various cancers by analyzing the urea cycle metabolites.

Yeda

Background and Unmet Need

Early stage diagnosis and treatment of cancer is essential, especially for highly malignant or metastatic tumors. An important stage in cancer progression is cell growth and proliferation, therefore cancer cells typically alter metabolic cycles to synthesize metabolites that are required for said processes. The urea cycle (UC) is one such important metabolic pathway that takes place in the liver. A variety of enzymes are involved in the UC, which converts excess nitrogen into urea and produces various metabolites during this process. The metabolites produced by the UC depend on the balance between its components, such as arginine-based metabolites on one hand and pyrimidines on the other. Therefore, the UC might provide diagnostic and therapeutic means to cancers which involve its alteration.

The Solution

The research team of Dr. Ayelet Erez discovered a correlation between UC enzymes and metabolites and the severity of cancer.

Technology Essence

The Erez group uncovered a link between changes in UC enzymes and cancer development. They discovered that alterations in UC enzymes, such as ASL, ASS1, and CPS1, are related to increased expression of the trifunctional enzyme CAD. Due to its role in pyrimidine synthesis, elevated CAD activity results in higher pyrimidine levels, which correlate with up-regulation of cancer cell proliferation. Analysis of plasma and urine samples in mouse cancer models as well as human patients shows higher levels of pyrimidine-related metabolites and reduction in urea compared to healthy counterparts. Thus, shifts in UC enzyme activity and metabolite synthesis are indicative of cancer state and can be used as a diagnostic tool, as well as potential point of intervention in treating cancer.

Applications and Advantages

  • Non-Invasive – Analysis of urine and plasma samples.
  • Multiple Applications – treating cancer by shifting UC-related metabolism, determining the severity of the disease, predicting the outcome of treatments, and more.

Development Status

Prof. Erez and her team conducted comprehensive research on the urea cycle and demonstrated that downregulation of UC enzymes can shift the metabolite balance towards CAD and induce pyrimidine synthesis and cancer cell line proliferation. The group also showed that there is correlation between dysregulation of UC genes, cancer prognosis and response to therapy in vivo using mouse model of colon cancer.

References

Lee, Joo Sang, Lital Adler, Hiren Karathia, Narin Carmel, Shiran Rabinovich, Noam Auslander, Rom Keshet, et al. 2018. “Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures.” Cell 174 (6): 1559–70.e22. [1]

Intellectual property status

  • Granted Patent
  • Patent application number :USA Published: Publication Number: 2020-0150125-A1

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Clinical Research, Trials
  • Biology / Biotechnology
  • Medical Health related
  • Diagnostic

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools

Yeda

Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide

Yeda

Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support